Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases.
Jansen Y, Kruse V, Corthals J, Schats K, van Dam PJ, Seremet T, Heirman C, Brochez L, Kockx M, Thielemans K, Neyns B. Jansen Y, et al. Among authors: van dam pj. Cancer Immunol Immunother. 2020 Dec;69(12):2589-2598. doi: 10.1007/s00262-020-02618-4. Epub 2020 Jun 26. Cancer Immunol Immunother. 2020. PMID: 32591862 Free PMC article. Clinical Trial.
International consensus guidelines for scoring the histopathological growth patterns of liver metastasis.
van Dam PJ, van der Stok EP, Teuwen LA, Van den Eynden GG, Illemann M, Frentzas S, Majeed AW, Eefsen RL, Coebergh van den Braak RRJ, Lazaris A, Fernandez MC, Galjart B, Laerum OD, Rayes R, Grünhagen DJ, Van de Paer M, Sucaet Y, Mudhar HS, Schvimer M, Nyström H, Kockx M, Bird NC, Vidal-Vanaclocha F, Metrakos P, Simoneau E, Verhoef C, Dirix LY, Van Laere S, Gao ZH, Brodt P, Reynolds AR, Vermeulen PB. van Dam PJ, et al. Among authors: van den eynden gg, van der stok ep, van de paer m, van laere s. Br J Cancer. 2017 Nov 7;117(10):1427-1441. doi: 10.1038/bjc.2017.334. Epub 2017 Oct 5. Br J Cancer. 2017. PMID: 28982110 Free PMC article.
Histopathological growth patterns as a candidate biomarker for immunomodulatory therapy.
van Dam PJ, Daelemans S, Ross E, Waumans Y, Van Laere S, Latacz E, Van Steen R, De Pooter C, Kockx M, Dirix L, Vermeulen PB. van Dam PJ, et al. Among authors: van steen r, van laere s. Semin Cancer Biol. 2018 Oct;52(Pt 2):86-93. doi: 10.1016/j.semcancer.2018.01.009. Epub 2018 Jan 31. Semin Cancer Biol. 2018. PMID: 29355613 Review.
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez MJ, Suarez C, Linch M, Prendergast A, van Dam PJ, Stanoeva D, Daelemans S, Mariathasan S, Tea JS, Mousa K, Banchereau R, Castellano D. Powles T, et al. Among authors: van dam pj, van der heijden ms. Nat Med. 2019 Nov;25(11):1706-1714. doi: 10.1038/s41591-019-0628-7. Epub 2019 Nov 4. Nat Med. 2019. PMID: 31686036 Free article. Clinical Trial.
A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab.
Awada G, Jansen Y, Schwarze JK, Tijtgat J, Hellinckx L, Gondry O, Vermeulen S, Warren S, Schats K, van Dam PJ, Kockx M, Keyaerts M, Everaert H, Seremet T, Rogiers A, Neyns B. Awada G, et al. Among authors: van dam pj. Cancers (Basel). 2021 Jan 6;13(2):168. doi: 10.3390/cancers13020168. Cancers (Basel). 2021. PMID: 33418936 Free PMC article.
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
Szabados B, Kockx M, Assaf ZJ, van Dam PJ, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez MJ, Suarez C, Linch M, Prendergast A, Tyson C, Stanoeva D, Daelemans S, Rombouts M, Mariathasan S, Tea JS, Mousa K, Sharma S, Aleshin A, Banchereau R, Castellano D, Powles T. Szabados B, et al. Among authors: van dam pj, van der heijden ms. Eur Urol. 2022 Aug;82(2):212-222. doi: 10.1016/j.eururo.2022.04.013. Epub 2022 May 14. Eur Urol. 2022. PMID: 35577646 Clinical Trial.
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez MJ, Suarez C, Linch M, Prendergast A, van Dam PJ, Stanoeva D, Daelemans S, Mariathasan S, Tea JS, Mousa K, Banchereau R, Castellano D. Powles T, et al. Among authors: van dam pj, van der heijden ms. Nat Med. 2020 Jun;26(6):983. doi: 10.1038/s41591-020-0923-3. Nat Med. 2020. PMID: 32555515
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez MJ, Suarez C, Linch M, Prendergast A, van Dam PJ, Stanoeva D, Daelemans S, Mariathasan S, Tea JS, Mousa K, Banchereau R, Castellano D. Powles T, et al. Among authors: van dam pj. Nat Med. 2023 Dec;29(12):3271. doi: 10.1038/s41591-023-02312-9. Nat Med. 2023. PMID: 36944799 No abstract available.
Fibroblast Activation Protein-α and the Immune Landscape: Unraveling T1 Non-muscle-invasive Bladder Cancer Progression.
Muilwijk T, Baekelandt L, Akand M, Daelemans S, Marien K, Waumans Y, van Dam PJ, Kockx M, Van den Broeck T, Van Cleynenbreugel B, Van der Aa F, Gevaert T, Joniau S. Muilwijk T, et al. Among authors: van dam pj. Eur Urol Open Sci. 2024 Jul 1;66:67-74. doi: 10.1016/j.euros.2024.06.011. eCollection 2024 Aug. Eur Urol Open Sci. 2024. PMID: 39044944 Free PMC article.
48 results